𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Tamoxifen and Risk of Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers

✍ Scribed by Phillips, K.-A.; Milne, R. L.; Rookus, M. A.; Daly, M. B.; Antoniou, A. C.; Peock, S.; Frost, D.; Easton, D. F.; Ellis, S.; Friedlander, M. L.; Buys, S. S.; Andrieu, N.; Nogues, C.; Stoppa-Lyonnet, D.; Bonadona, V.; Pujol, P.; McLachlan, S. A.; John, E. M.; Hooning, M. J.; Seynaeve, C.; Tollenaar, R. A. E. M.; Goldgar, D. E.; Terry, M. B.; Caldes, T.; Weideman, P. C.; Andrulis, I. L.; Singer, C. F.; Birch, K.; Simard, J.; Southey, M. C.; Olsson, H. L.; Jakubowska, A.; Olah, E.; Gerdes, A.-M.; Foretova, L.; Hopper, J. L.

Book ID
121425998
Publisher
American Society of Clinical Oncology
Year
2013
Tongue
English
Weight
142 KB
Volume
31
Category
Article
ISSN
0732-183X

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Tamoxifen and contralateral breast cance
Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: An update
✍ Jacek Gronwald; Nadine Tung; William D. Foulkes; Kenneth Offit; Ruth Gershoni; M πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 French βš– 77 KB

## Abstract Women with a mutation in __BRCA1__ or __BRCA2__ face a lifetime risk of breast cancer of ∼80%, and following the first diagnosis the10‐year risk of contralateral breast cancer is ∼30%. It has been shown that both tamoxifen and oophorectomy prevent contralateral breast cancer, but it is